Clinical trial
Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects…
NCT00381238 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00381238 |
|---|---|
| Title | Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease |
| Official title | An Open-label Extension to Study 49653/461, to Assess the Long-term Safety of Rosiglitazone (Extended Release Tablets) in Subjects With Mild to Moderate Alzheimer's Disease |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Alzheimer's Disease |
| Intervention type | Drug |
| Interventions | rosiglitazone |
| Enrollment | 33 |
| Start date | Jun 20, 2006 |
| Primary completion | Feb 1, 2009 |
| Completion | Feb 3, 2009 |
| First posted | Sep 27, 2006 |
| Last update posted | May 23, 2017 |
| Countries | Canada, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: